Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO

May 19, 2021

Positive Data on RECCE 327 Against All Six ESKAPE Pathogens

May 3, 2021

RECCE 327 Registered for Topical Burns Study in Humans

April 15, 2021

Positive Sinusitis Patient Update - Special Access Scheme

April 7, 2021

Positive Sinusitis Data Against Infection

March 31, 2021

Anti-Viral Patent Granted in EU for RECCE Anti-Infectives

March 30, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange

March 7, 2021

Appendix 4D and Half Yearly Report

February 25, 2021

Recce Applies for Dual Listing on Frankfurt Stock Exchange

February 23, 2021

Fiona Stanley Hospital Phase I/II Clinical Trial Agreement

February 15, 2021

Further Encouraging COVID Results at Doherty

February 11, 2021

R&D Incentive Rebate Received

February 3, 2021

Positive Intranasal Animal Data against SARS-CoV-2 in Study

December 22, 2020

RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding

December 7, 2020

Recce Awarded AusIndustry Advanced Overseas (R&D) Finding

November 25, 2020

Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives

November 22, 2020

Encouraging Results Against SARS-CoV-2 Virus

November 10, 2020

HREC Approval to Start Phase I/II Burns Wound Study

October 15, 2020

Murdoch Childrens Research Institute, R435 Against H.Pylori

September 30, 2020

Recce Completes Capital Raising of $27.95m

September 23, 2020

R327 Phase I Study - Australias CMAX Clinical Facility

September 10, 2020

Positive & Concentration-Dependent Efficacy Against COVID-19

September 8, 2020

Recce Pharmaceuticals Receives Innovation Connections Grant

August 31, 2020

Recce Pharmaceuticals Appoints James Graham as CEO

August 28, 2020

Positive Oral Data on New RECCE 435 Against H. pylori

August 4, 2020

US Researchers to Test RECCE in Expanded SARS-CoV-2 Program

July 16, 2020

RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program

July 8, 2020

Response to ASX Price and Volume Query

May 27, 2020

Positive Data on RECCE 327 Against Neisseria gonorrhoeae

May 4, 2020

Further Positive Data on RECCE 327 Against MRSA Superbug

April 23, 2020

Positive Data on RECCE 327 Against Influenza A

April 20, 2020

Recce Signs Phase I Human Clinical Trial Agreement

April 8, 2020

First-in-Human Clinical Trial Progress Update

March 16, 2020

Half Yearly Report and Accounts

February 27, 2020

Positive Efficacy Data in Kidney/UTI infections animal model

February 13, 2020

Positive Data from RECCE 327 Antibiotic Safety Studies

February 9, 2020

Appendix 4C and Commentary

January 31, 2020

Positive Data for RECCE 327 in MRSA Burns Wound Infection

November 26, 2019

Recce Completes Raising of $6.76 million

October 9, 2019

Key Family 2 Patent Granted in Japan for RECCE Antibiotics

September 20, 2019

Funding Update

September 11, 2019

Appendix 4E - Preliminary Final Report

August 30, 2019

FDA Positive Response for Recce Scaled Manufacture & Quality

August 26, 2019

Response to ASX Appendix 4C Query

August 16, 2019

Key Family 2 Patent Granted in Europe for RECCE Antibiotics

August 8, 2019

Opening R&D Address at World Antibiotic Resistance Congress

July 31, 2019

Appendix 4C and commentary

July 30, 2019

Appointment of Independent Chair and Additional Director

July 9, 2019

USA Patent Granted for Recces Antibiotics

March 13, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 26 decks. Every deck is listed under its year.